Ibrutinib With Immunochemotherapy/ASCT Improves MCL Survival
Episode Summary
Adding ibrutinib to frontline therapy improves failure-free survival in younger mantle cell lymphoma patients and may reduce routine transplant use, though infection and blood toxicity risks increase.